Report cover image

Regenerative Medicine in Pharma Market Size, Share and Trends Analysis by Region, Drug Class (Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics, Others), Route of Administration (Injectable, Oral, Topical), and Segment Forecast, 2022-202

Publisher GlobalData
Published Nov 10, 2022
Length 119 Pages
SKU # GBDT17548645

Description

Regenerative Medicine in Pharma Market Size, Share and Trends Analysis by Region, Drug Class (Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics, Others), Route of Administration (Injectable, Oral, Topical), and Segment Forecast, 2022-2027

Summary

The Regenerative Medicine in Pharma market size was valued at US$29.4 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 11.1% during 2022-2027. The Regenerative Medicine in Pharma market report provides an executive-level overview of the regenerative medicine market worldwide today, with detailed forecasts of key indicators up to 2027.

This market intelligence report offers a thorough, forward-looking analysis of the Regenerative Medicine in Pharma market, and key product and platform stack in a concise format to help executives build proactive and profitable growth strategies.

The regenerative medicine in pharma market size was valued at US$29.1 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 11.1% during the forecast period (2022-2027). The market is driven by the growing prevalence of chronic diseases, genetic disorders, and cancer and technological advancements in stem-cell therapies.

Scope
  • Overview of regenerative medicine in pharma market including industry trends, funding & deals, pipeline analysis, regulatory details, and product & company profile
  • Regenerative medicine in pharma market outlook: analysis as well as historical figures and forecasts of revenue opportunities from the product, technology, application, and geographic segments.
  • Regenerative medicine in pharma market outlook: analysis as well as forecasts of revenue opportunities from the drug class segments.
  • Regenerative medicine in pharma market outlook: analysis as well as forecasts of revenue opportunities from the route of administration segment.
  • The competitive landscape: an examination of the positioning of leading players in regenerative medicine in pharma market.
Reasons to Buy
  • This market intelligence report offers a thorough, forward-looking analysis of the Regenerative Medicine in Pharma market and key opportunities in a concise format to help executives build proactive and profitable growth strategies.
  • Accompanying GlobalData’s Forecast products, the report examines the assumptions and drivers behind ongoing and upcoming trends in regenerative medicine in pharma markets.
  • The report also highlights key product, therapeutic area segments.
  • With different charts and tables, the report is designed for an executive-level audience, boasting presentation quality.
  • The report provides an easily digestible market assessment for decision-makers built around in-depth information gathered from market players, which enables executives to quickly get up to speed with the current and emerging trends in regenerative medicine in pharma market.

Table of Contents

119 Pages
    • Regenerative Medicine in Pharma Market Snapshot
    • Regenerative Medicine in Pharma Market- Key Findings
    • Market Definition
    • Market Scope and Segmentation
    • Industry Trends
    • Opportunities in Regenerative Medicine in Pharma
    • Regenerative Medicines in Clinical Trials
    • Value Chain Analysis
    • Fig.10 Stages of Clinical Development of Regenerative Medicine
    • Differences Between Conventional Therapies and Stem Cell Therapies in Clinical Trials
    • US
    • Europe
    • Regulation of Regenerative Medicine in the US and Europe
    • Japan
    • South Korea
    • Overview
    • Fig.15 Pipeline Products by Type, Phase, and Therapy Area
    • Late-Stage Gene Therapy Products
    • Late-Stage Gene-Modified Cell Therapy Products
    • Late-Stage Cell Therapy Products
    • Late-Stage Tissue-Engineered Treatment
    • Regenerative Medicine in Pharma Market Structure – PORTER’s Analysis
    • Deals in Regenerative Medicine in Pharma
    • Funding in Regenerative Medicine in Pharma
    • Global Regenerative Medicine in Pharma Market
    • COVID-19 Pandemic
    • Regenerative Medicine in Pharma – Product Dive
    • Regenerative Medicine in Pharma – Therapeutic Area Dive
    • Regenerative Medicine in Pharma – Regional Deep Dive
    • Regenerative Medicine in Pharma – Market Trends
    • Regenerative Medicine in Pharma – Market Drivers
    • Regenerative Medicine in Pharma – Market Challenges
    • COMPANY SNAPSHOT: NOVARTIS AG
    • COMPANY SNAPSHOT: GILEAD
    • COMPANY SNAPSHOT: AMGEN
    • COMPANY SNAPSHOT: BRISTOL-MYERS SQUIBB COMPANY
    • COMPANY SNAPSHOT: BLUE BIRD BIO
    • COMPANY SNAPSHOT: JOHNSON & JOHNSON
    • COMPANY SNAPSHOT: BIOMARIN PHARMACEUTICAL INC
    • COMPANY SNAPSHOT: PTC THERAPEUTICS
    • COMPANY SNAPSHOT: ORCHARD THERAPEUTICS
    • COMPANY SNAPSHOT: VERICEL CORPORATION
    • Methodology
    • About US

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us